QVAR is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for the systemic corticosteroids.
Beclomethasone dipropionate is NOT indicated for the relief of acute bronchospasm.
ADVAIR HFA is indicated for the long-term, twice-daily maintenance treatment of asthma in patients 12 years of age and older.
Long-acting beta2-adrenergic agonists, such as salmeterol, one of the active ingredients in ADVAIR HFA, may increase the risk of asthma-related death (see WARNINGS). Therefore, when treating patients with asthma, physicians should only prescribe ADVAIR HFA for patients not adequately controlled on other asthma-controller medications (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with 2 maintenance therapies. ADVAIR HFA is not indicated in patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of inhaled, short-acting beta2-agonists.
ADVAIR HFA is NOT indicated for the relief of acute bronchospasm.
It is not recommended after reading the above, please seek medical attention before you switch meds, hope it helps?
- Qvar Information for Consumers
- Qvar Information for Healthcare Professionals (includes dosage details)
- Side Effects of Qvar (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 5 Jan 2010 • 1 answer
Posted 18 Jan 2010 • 1 answer
Posted 3 Nov 2011 • 1 answer
Posted 20 Aug 2012 • 1 answer
Posted 30 Mar 2015 • 1 answer